Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 5 Issue 1

Immunological, Pharmacological, Pharmacokinetics, Therapeutic Targets and Various Therapy for SARS-CoV-2: Recent Advancement and Future Prospective

Abhishek Kumar Verma1* , Zaharaddeen Umar Na’abba1, Najib Lawan Yahaya1, Mudassir Alam2, Mudassir Lawal1, Binta Sunusi Shuaibu1, Umar Adamu Hamza1, Usman Rabi'u Bello1, Abubakar Dabo Dalhat1 and Mayadhar Barik1*

1Department of Life Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
2Department of Zoology, Aligarh Muslim University, Aligarh, Uttar Pradesh, India

*Corresponding Author: Abhishek Kumar Verma, Assistant Professor, Department of Life Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.

Received: July 15, 2020; Published: December 30, 2020

×

Abstract

  Severe acute respiratory syndrome 2 (SARS-CoV- 2) is a novel coronavirus that causes coronavirus disease 2019 (COVID-19), an infection characterized by flu-like symptoms, progressing in some cases to acute respiratory distress syndrome (ARDS). That WHO to declare it as global pandemic. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), effort are put in place to develop effective therapeutic agent against the COVID-19. Currently, there is no therapeutic candidate for this virus but the United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine and other promising antiviral drugs. Although the result of ongoing clinical trials are not out, but some provide promising result in vitro. The most important factor associated with pathophysiology of SARS-CoV-2 is the host immune response which results due to binding of spike glycoprotein to its receptor angiotensin-converting enzyme 2 (ACE2) but concerned has arose for the continuous expressing of ACE in affected patient especially patient with pregnancy as this might increase the susceptibility of the patient although there is no strong evidence for it involvement for susceptibility of the affected patients. Despite the continuous evolving and dynamics on the literature of COVID-19, using the existing knowledge, possible drug target have been identified for the development of the effective vaccine. Since there is no effective therapeutic drug for the current pandemic, drug repurposing might be a viable strategy and specific prophylaxis regimen should be provide to reduce the toxicity on the affected patients and the clinical trial should be based on the specificity and efficacy of the drug. This review provide information on the Novel invention and new guidelines or protocol for SARS-COV-2.

Keywords: Immunological; Pharmacological; Theraputics Targets; Recent Advancements; SARS-CoV-2

×

References

  1. Astuti I. “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response”. Diabetes and Metabolic Syndrome: Clinical Research Reviews4 (2020): 407–412.
  2. Price M E., et al. “A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy”. British Medical Journal6648 (1988): 584-587.
  3. Rathi S., et al. “Hydroxychloroquine prophylaxis for COVID-19 contacts in India”. The Lancet Infectious Diseases (2020).
  4. Agostini M L., et al. “Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease”. MBio2 (2018).
  5. Singh A K., et al. “Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2020).
  6. Singhai T. “A review of the coronavirus disease-2019”. Indian Journal of Pediatrics 87 (2020): 281-286.
  7. Gebrie D., et al. “Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials”. BMJ Open6 (2020): e039159.
  8. Zhao X., et al. “Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening”. European Journal of Clinical Microbiology and Infectious Diseases 1 (2020): 1-12.
  9. Caly L., et al. “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro”. Antiviral Research 178 (2020): 104787.
  10. Mayadhar Barik., et al. “Molecular Screening and Diagnosis of SARS-CoV-2: Recent Advances and Future Prospective". Acta Scientific Microbiology7 (2020): 46-51.
  11. Colson P., et al. “Chloroquine for the 2019 novel coronavirus SARS-CoV-2”. International Journal of Antimicrobial Agents 3 (2020): 105923.
  12. Lawal M., et al. “Analysis of New Potent Anti-Diabetic Molecules from Phytochemicals of Pistia Strateotes with Sglt1 and G6pc Proteins of Homo Sapiens For Treatment Of Diabetes Mellitus”. An In Silico Approach.
  13. Furuta Y., et al. “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase”. Proceedings of the Japan Academy, Series B7 (2017): 449-463.
  14. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends1 (2020): 72-74.
  15. Gautret P., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-ran-Потенциальная иммунопрофилактика COVID-19 у групп высокого риска инфицирования domized clinical trial”. International Journal of Antimicrobe Agents (2020): 105949.
  16. Cai Q., et al. “Experimental treatment with favipiravir for COVID-19: an open-label control study”. Engineering (2020): S2095809920300631.
  17. Graci JD and Cameron C E. “Mechanisms of action of ribavirin against distinct viruses”. In Reviews in Medical Virology 16.1 (2006): 37-48.
  18. Yao X., et al. “In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)”. Clinical Infectious Diseases (2020).
  19. Liu J., et al. “Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro”. Cell Discovery1 (2020): 1-4.
  20. Verma A K., et al. “Inhibition of multidrug resistance property of Candida albicans by natural compounds of parthenium hysterophorus L. An In-Silico approach”. Journal of Pharmacognosy and Phytochemistry3 (2020): 55-64.
  21. Zaharaddeen Umar Na’abba and Abhishek Kumar Verma. “Pharmacological Treatments and Development of SARS-CoV-2”. Acta Scientific Pharmaceutical Sciences9 (2020): 01-02.
  22. Warren T K., et al. “Discovery and Synthesis of GS-5734, a Phosphoramidate Prodrug of a Pyrrolo 2, 1 ftriazin 4 amino Adenine C-Nucleoside (GS 5734) for the Treatment of Ebola and Emerging Viruses (No. TR-17-031)”. USAMRIID Ft Detrick United States (2017).
  23. Şimşek Y S and Ünal S. “Antiviral treatment of COVID-19”. Turkish Journal of Medical Sciences 50 (2020): 611-619.
  24. Singh A K., et al. “Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews3 (2020): 241-246.
  25. Tchesnokov E P., et al. “Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir”. Viruses4 (2019): 326.
  26. Tu Y F., et al. “A review of SARS-CoV-2 and the ongoing clinical trials”. International Journal of Molecular Sciences 7 (2020): 2657.
  27. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research3 (2020): 269-271.
  28. Wu C Y., et al. “Small molecules targeting severe acute respiratory syndrome human coronavirus”. Proceedings of the National Academy of Science27 (2004): 10012-10017.
  29. Yan J., et al. “Research Progress of Drug Treatment in Novel Coronavirus Pneumonia”. AAPS PharmSciTech 21 (2020): 1-6.
  30. Dan Z., et al. “COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression”. Journal of Antimicrobial Chemotherapy (2020): 1-4.
  31. Maurya S K., et al. “Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2”. Journal of Receptors and Signal Transduction (2020): 1-8.
  32. Arabi Y M., et al. “Critical care management of adults with community-acquired severe respiratory viral infection”. Intensive Care Medicine2 (2020): 315-328.
  33. Braciale T J and Hahn Y S. “Immunity to viruses”. Immunological Reviews1 (2020).
  34. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.
  35. Abhishek Kumar Verma., et al. “Virtual Screening, Molecular Docking, and ADME/T Analysis of Natural Product Library against Cell Invasion Protein SipB from Salmonella enterica serotype typhi: In Silico Analysis”. Acta Scientific Pharmaceutical Sciences8 (2020): 20-30.
  36. Channappanavar R., et al. “Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice”. Cell Host and Microbe2 (2016): 181-193.
  37. Chen Z., et al. “Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial”. medRxiv (2020).
  38. Chong C R and Sullivan Jr D J. “Inhibition of heme crystal growth by antimalarials and other compounds: implications for drug discovery”. Biochemical Pharmacology11 (2003): 2201-2212.
  39. Cron R Q and Behrens E M. “Cytokine storm syndrome”. Springer Nature (2019).
  40. Duret P M., et al. “Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept”. Annals of the Rheumatic Diseases (2020).
  41. Meng L., et al. “Intubation and Ventilation amid the COVID-19 OutbreakWuhan’s Experience”. Anesthesiology: The Journal of the American Society of Anesthesiologists6 (2020): 1317-1332.
  42. Fox RI. “Mechanism of action of hydroxychloroquine as an antirheumatic drug”. In Seminars in Arthritis and Rheumatism 23.2 (1993): 82-91.
  43. Franzetti M., et al. “Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report”. International Journal of Infectious Diseases (2020).
  44. Valentini M and Zmerly H. “Antirheumatic drugs for COVID-19 treatment based on the phases of the disease”. Journal of Population Therapeutics and Clinical PharmacologySP1 (2020): e14-e25.
  45. Mayadhar Barik., et al. “Impact of Media and Protocol on SARS-CoV-2: Statistical Analysis". Acta Scientific Pharmaceutical Sciences 9 (2020): 40-47.
  46. Katzung B G and Trevor A J. “Basic and Clinical Pharmacology, SMARTBOOKTM”. McGraw Hill Professional (2014).
  47. M Bhatia., et al. “Role of chemokines in the pathogenesis of acute lung injury”. American Journal of Respiratory Cell and Molecular Biology 5 (2012): 566-572.
  48. Mehra M R., et al. “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”. The Lancet (2020).
  49. Ortiz-Sanjuán F., et al. “Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review”. Medicine39 (2015).
  50. Ismail M., et al. “Possible Mechanical Transmission of SARS-CoV-2 Causing COVID-19 by Insects: Infection, Prevention, Implications, and Control”. Open Journal of Medical Microbiology2 (2020): 89-101.
  51. gov t. “A Pilot Study of Duvelisib to Combat COVID-19”. Identification no: NCT04372602 (2020).
  52. gov t. “Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure (TXACOVIDPREV)”. Identification no: NCT04550338 (2020).
  53. govt. “Estrogen Patch for COVID-19 Symptoms”. Identification no: NCT04359329 (2020).
  54. govt. “A phase ii trial to evaluate the safety and tolerability of clazakizumab compared to placebo for the treatment of covid-19 infection”. Identification no: NCT04494724 (2020).
  55. govt. “Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation”. Identification no: NCT04447469 (2020).
  56. govt. “Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19 (COVID-19)”. Identification no: NCT04336462 (2020).
  57. govt. “Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT (BEST-RCT)”. Identification no: NCT04305106 (2020).
  58. govt. “ (2020). A Pilot Study of Sildenafil in COVID-19”. Identification no: NCT04304313 (2020).
  59. govt. “Moxibustion Plus Cupping in Convalescent Patients With COVID-19”. Identification no: NCT04374084 (2020).
  60. govt. “Fingolimod in COVID-19”. Identification no: NCT04280588 (2020).
  61. govt. “A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia”. Identification no: NCT04255017 (2020).
  62. govt. “ (2020). A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia”. Identification no: NCT04254874.
  63. govt. “Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 (DC-COVID-19)”. Identification no: NCT04252274 (2020).
  64. govt. “Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients (X-Covid 19)”. Identification no: NCT04366960 (2020).
  65. Huilgol N G. “Stalling cytokine storm in patients with COVID-19 infection with low-dose radiation”. Journal of Radiation and Cancer Research1 (2020): 1.
  66. govt. “Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia (TOSCA)”. Identification no: NCT04332913 (2020).
  67. govt. “Escin in Patients With Covid-19 Infection (add-on-COV2)”. Identification no: NCT04322344 (2020).
  68. govt. “Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection”. Identification no: NCT04324021 (2020).
  69. govt. “Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)”. Identification no: NCT04361526 (2020).
  70. govt. “Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19”. Identification no: NCT04420299 (2020).
  71. Chaccour C., et al. “The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial”. Trials1 (2020): 1-4.
  72. govt. “Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection”. Identification no: NCT04367883 (2020).
  73. govt. “A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19. Identification no: NCT03891420 (2020).
  74. Ministry of Health and Family welare of India, N. A. C. O. “Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents” (2013): 40-45.
  75. Bergmann CC., et al. “Coronavirus infection of the central nervous system: host-virus stand-off”. Nature Reviews Microbiology 2 (2006): 121-132.
  76. Asai A., et al. “COVID-19 drug discovery using intensive approaches”. International Journal of Molecular Sciences8 (2020): 2839.
  77. Heim C., et al. “Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood”. JAMA5 (2000) 592-597.S

 

×

Citation

Citation: Abhishek Kumar Verma, Mayadhar Barik., et al. “Immunological, Pharmacological, Pharmacokinetics, Therapeutic Targets and Various Therapy for SARS-CoV-2: Recent Advancement and Future Prospective". Acta Scientific Pharmaceutical Sciences 5.1 (2020): 110-143.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US